StimAire, Inc.

StimAire, Inc. specializes in creating innovative solutions for obstructive sleep apnea through a minimally invasive device that stimulates the hypoglossal nerve, offering a new approach for patient care without traditional CPAP equipment. StimAire, Inc. was founded in 2017 in Tucson, US, to develop a unique treatment for obstructive sleep apnea.

The company was established by Tarek Makansi, who has a history in entrepreneurship. As of November 2019, StimAire raised an undisclosed amount in SERIES A funding, marking its first investment round. The firm has completed one deal to date. StimAire focuses on an innovative treatment for obstructive sleep apnea, featuring a rice-grain-sized device that is implanted via injection under local anesthesia.

This device, designed to stimulate the hypoglossal nerve, is complemented by a peel-and-stick wearable that prevents airway obstruction during sleep. The primary market involves U. S. patients, with plans for potential international expansion as clinical approvals progress.

StimAire's revenue model is based on the commercialization of its investigational device, which is not yet approved for clinical use. The company expects to generate revenue through sales to healthcare providers and partnerships with medical institutions post-regulatory approval. Direct-to-consumer sales through healthcare providers are also anticipated, alongside collaborations with sleep medicine specialists. The device's introduction will follow successful clinical trials, which will help set pricing and reimbursement strategies.

In November 2019, StimAire secured SERIES A funding, which will support its growth initiatives. The company plans to launch its device following clinical trials, targeting the U. S. market initially, with aspirations to expand internationally thereafter.

As the product approaches regulatory approval, StimAire will focus on establishing market strategies and pricing frameworks to effectively penetrate new markets.